Sai Parenteral's

Why is Sai Parenterals Ltd falling/rising?

As of 03-Jul, Sai Parenterals Ltd's stock price is at 619.85, down 0.62% after three days of gains, indicating a trend reversal. Despite this decline, the stock has performed well over the past week and month, significantly outperforming the Sensex, while showing strong investor interest.

As of 03-Jul, Sai Parenterals Ltd's stock price is currently at 619.85, reflecting a decrease of 3.85 points or 0.62%. This decline comes after a period of three consecutive days of gains, indicating a trend reversal. Despite this recent drop, the stock has shown strong performance over the past week, with a return of 5.70%, significantly outperforming the Sensex, which only increased by 0.86%. <BR><BR>In the past month, the stock has risen by 24.14%, again surpassing the Sensex's 4.60% increase. However, today's performance has underperformed the sector by 1.66%. The weighted average price suggests that more volume was traded closer to the low price, which could indicate selling pressure. <BR><BR>On a positive note, Sai Parenterals Ltd is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, which typically signals a bullish trend. Additionally, there has been a notable increase in investor participation, with delivery volume rising by 235.39% against the 5-day average. This suggests that while the stock is currently experiencing a decline, there is still significant interest from investors. <BR><BR>Overall, the stock's recent fall can be attributed to a trend reversal after a series of gains, combined with today's underperformance relative to the sector, despite strong overall returns in the past week and month.

Which are the latest news on Sai Parenteral's?

What does Sai Parenteral's do?

Sai Parenterals Ltd is a small-cap company in the Pharmaceuticals & Biotechnology industry, specializing in parenteral products. As of March 2026, it reported net sales of ₹57 Cr and a net profit of ₹10 Cr, with a market cap of ₹2,479 Cr.

Overview: <BR>Sai Parenterals Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Small Cap company.<BR><BR>History: <BR>Sai Parenterals Ltd was originally incorporated as 'Sai Parenteral's Private Limited' in 2001. The company transitioned to a Public Limited Company and changed its name to 'Sai Parenteral's Limited' on January 17, 2022. The most recent quarterly results reported net sales and net profit for the period ending March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 57 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 10 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 2,479 Cr (Small Cap)<BR><BR>Key Metrics: <BR>P/E: 172.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.17 <BR>Return on Equity: 2.91% <BR>Price to Book: 5.04<BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

How big is Sai Parenteral's?

As of 10th June, Sai Parenterals Ltd has a market capitalization of 2,479.00 Cr, with recent Net Sales of 294.08 Cr and a Net Profit of 6.50 Cr for the quarters ending March 2026 and December 2025.

As of 10th June, Sai Parenterals Ltd has a market capitalization of 2,479.00 Cr, categorizing it as a Small Cap company.<BR><BR>In the latest two quarters, the company reported Net Sales of 294.08 Cr and a Net Profit of 6.50 Cr. This reflects the financial performance for the quarters ending March 2026 and December 2025.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 93.67 Cr and Total Assets valued at 271.86 Cr.

Who are the peers of the Sai Parenteral's?

Sai Parenteral's peers include Unichem Labs, Novartis India, Solara Active, and others, with varying management risk and growth ratings. Venus Remedies leads in 1-year returns at 270.28%, while Dishman Carbogen has the lowest at -38.51%.

Peers: The peers of Sai Parenteral's are Unichem Labs., Novartis India, Solara Active, Dishman Carbogen, Morepen Labs., Kwality Pharma, Venus Remedies, Hikal, Indoco Remedies, and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Novartis India, Venus Remedies, and the rest have Average management risk, including Unichem Labs., Morepen Labs., Kwality Pharma, Hikal, Indoco Remedies, and Sakar Healthcare. Below Average management risk is found at Solara Active and Dishman Carbogen. Growth is rated as Excellent for Novartis India, Venus Remedies, and Kwality Pharma, while Good growth is seen at Unichem Labs. and Dishman Carbogen. The rest, including Solara Active, Morepen Labs., Hikal, Indoco Remedies, and Sakar Healthcare, exhibit Below Average growth. Capital Structure is Excellent for Novartis India, Morepen Labs., and Kwality Pharma, while Good is seen at Unichem Labs. The rest, including Solara Active, Dishman Carbogen, Hikal, Indoco Remedies, and Sakar Healthcare, have Below Average capital structure.<BR><BR>Return Snapshot: Venus Remedies has the highest 1-year return at 270.28%, while Dishman Carbogen has the lowest at -38.51%. Sai Parenteral's 1-year return is not available for comparison. Additionally, Hikal and Dishman Carbogen have negative six-month returns.

When is the next results date for Sai Parenterals Ltd?

Sai Parenterals Ltd will announce its results on 23 May 2026.

Sai Parenterals Ltd is scheduled to declare its results on 23 May 2026.